The Latest Cardiac and Vascular News
New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy TITUSVILLE, N.J., July 30, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) injection […]
Data from the SPHERE Registry published in the Journal of Heart and Lung Transplantation SOUTH SAN FRANCISCO, Calif., April 6, 2021 /PRNewswire/ — Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found […]
Application seeks approval of XARELTO® plus aspirin to reduce the risk of major thrombotic vascular events in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) XARELTO® is currently approved to reduce the risk of major cardiovascular events, […]
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UPTRAVI® (selexipag) as an injection for intravenous (IV) use for the treatment […]
XARELTO® has the potential to be the first anticoagulant in 20 years(i) to show a benefit in these high-risk patients Two major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease RARITAN, N.J., March […]
Highlights include four late-breaking XARELTO® (rivaroxaban) abstracts Four INVOKANA® (canagliflozin) abstracts from the pivotal CREDENCE study will also be presented RARITAN, N.J., March 20, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking […]
Johnson & Johnson, in collaboration with Apple, is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading the Heartline Study app on iPhone Study aims to assess whether the Heartline Study app […]
CHIEF-HF is the first-ever completely decentralized, mobile, indication-seeking study assessing effectiveness of INVOKANA® (canagliflozin) in adults with heart failure (HF), with or without type 2 diabetes (T2D) Company tests innovative trial design with potential to bring medicines to patients faster […]
RARITAN, N.J., Nov. 1, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 46 company-sponsored and more than 37 investigator-led abstracts will be presented at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, CA on December 1-4. Highlights include eight company-sponsored […]
MUNICH, Aug. 27, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results of the Phase 3 MARINER and COMMANDER HF (heart failure) studies, which were presented this week at the European Society of Cardiology (ESC) Congress 2018 and simultaneously published in The […]
